- I Peace launches an HLA homozygous iPSC line, compatible with over 100 million Americans.
- New product aimed at reducing immune rejection risk in cell therapies for widespread clinical use.
I Peace, Inc., a GMP cell and gene therapy CDMO has announced the launch of its latest GMP-grade induced pluripotent stem cell (iPSC) line, which is homozygous for key HLA types. Developed from a healthy 26-year-old donor, the line provides compatibility across HLA A, C, and DPA1, targeting a significant population segment. This new line aims to improve access to compatible cell therapies for an estimated 100 million people in the U.S.
The new line is designed to address the need for HLA-matched cell lines, which play a crucial role in cell transplantation. HLA compatibility can reduce immune rejection and improve transplant success rates, which is especially beneficial for those undergoing allogeneic therapies. With this product, I Peace seeks to bridge the gap until autologous iPSC therapies become more widely available.
For cell therapy developers and pharmaceutical companies, the line is offered in both GMP and research grades. Dr. Koji Tanabe, CEO of I Peace, explained, “While autologous therapies are our ultimate goal, this HLA-matched line brings us closer to making allogeneic cell therapy viable and accessible to millions.” The product also offers potential benefits for individuals with congenital gene disorders.
Overview of outsourcing trends 
